Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avigen discontinues Coagulin B, restructures

AVGN discontinued development of its Coagulin B for hemophilia in order to focus on neurological disorders. The

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE